Biblio

Cortot A, Couraud S, Eisinger F, Touboul C, Blay J-Y, Viguier J, Lhomel C, Pivots X, Morere J-F, Greillier L.  2017.  Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey. JOURNAL OF THORACIC ONCOLOGY. 12:S566-S567.

Verger JDu.  2016.  ``Believe me when I swear, for I cannot tell a single lie'': Teofilo Folengo's Calculated Publishing Strategies. MOREANA. 53:225-268.

Boustani J., R. Del Campo R, Blanc J., Peiffert D., Benezery K., Pereira R., Rio E., Le Prise E., Crehange G., Huguet F..  2019.  Benchmark case in the ongoing PRODIGE 26 trial : quality assurance of dose escalated radiatherapy. RADIOTHERAPY AND ONCOLOGY. 133:S190.

Bunsell A, Gorbatikh L, Morton H, Pimenta S, Sinclair I, Spearing M, Swolfs Y, Thionnet A.  2018.  Benchmarking of strength models for unidirectional composites under longitudinal tension. COMPOSITES PART A-APPLIED SCIENCE AND MANUFACTURING. 111:138-150.

Biurrun I, Pielech R, Dembicz I, Gillet F, Kozub L, Marceno C, Reitalu T, Van Meerbeek K, Guarino R, Chytry M et al..  2021.  Benchmarking plant diversity of Palaearctic grasslands and other open habitats. JOURNAL OF VEGETATION SCIENCE. 32:e13050.

Anzid H, Le Goic G, Bekkari A, Mansouri A, Mammass D.  2018.  Benchmarking Saliency Detection Methods on Multimodal Image Data. IMAGE AND SIGNAL PROCESSING (ICISP 2018). 10884:11-18.

Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T et al..  2016.  Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. ONCOTARGET. 7:85573-85583.

de Guibert S, Dilhuydy M-S, Ysebaert L, Sanhes L, Choquet S, Aurran-Schleinitz T, Guieze R, Mahe B, Daguindau N, Araujo C et al..  2014.  Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial. BLOOD. 124

Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X et al..  2019.  Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). BRITISH JOURNAL OF HAEMATOLOGY. 186:146-149.

Reboursiere E, Le Bras F, Morschhauser F, Gyan E, Clavert A, Malak S, Sibon D, Damge M, Gardin C, Fornecker L-M et al..  2015.  Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study. BLOOD. 126

Chantepie S, Tchernonog E, Peyrade F, Larcher M-V, Diouf M, Fornecker LMathieu, Houot R, Gastinne T, Soussain C, Malak S et al..  2016.  Bendamustine-Based (BeEAM) Conditioning before Autologous Stem Cell Transplantation: Result of a French Multicenter Study of 386 Patients from Lysa Centers. BLOOD. 128

Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher M-V, Diouf M, Fornecker L-M, Houot R, Gastinne T, Soussain C et al..  2018.  Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. AMERICAN JOURNAL OF HEMATOLOGY. 93:729-735.

Lapierre B, Boumendil A, Creveuil C, Garciaz S, Peyrade F, Finel H, Khvedelidze I, Malak S, Lemal R, Larcher MVirgine et al..  2019.  Bendamustine-based versus BEAM conditioning regimen. A matched controlled study in diffuse large B-cell lymphoma from LYSA and LWP-EBMT. BONE MARROW TRANSPLANTATION. 54:58-59.

Lapierre B, Boumendil A, Creveuil C, Garciaz S, Peyrade F, Finel H, Khvedelidze I, Malak S, Lemal R, Larcher MVirgine et al..  2019.  Bendamustine-based versus BEAM conditioning regimen. A matched controlled study in diffuse large B-cell lymphoma from LYSA and LWP-EBMT. BONE MARROW TRANSPLANTATION. 54:58-59.

Costes-Tertrais D, Hueso T, Gastinne T, Thieblemont C, Oberic L, Bouabdallah K, Garciaz S, Tchernonog E, Dartigeas C, Ribrag V et al..  Submitted.  Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. BONE MARROW TRANSPLANTATION.

Song Y, Todorovic DM, Cretin B, Vairac P, Xu J, Bai J.  2014.  Bending of Semiconducting Cantilevers Under Photothermal Excitation. INTERNATIONAL JOURNAL OF THERMOPHYSICS. 35:305-319.

Nguyen D.T, Bouguet V., Spranghers T., Vangansbeke D., De Clercq P..  2015.  Beneficial effect of supplementing an artificial diet for Amblyseius swirskii with Hermetia illucens haemolymph. JOURNAL OF APPLIED ENTOMOLOGY. 139:342-351.

Roche J, Isacco L, Perret F, Dumoulin G, Gillet V, Mougin F.  2019.  Beneficial effects of a lifestyle intervention program on C-reactive protein: impact of cardiorespiratory fitness in obese adolescents with sleep disturbances. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY. 316:R376-R386.

Roche J., Isacco L., Perret F., Dumoulin G., Gillet V., Mougin F..  2018.  Beneficial effects of a lifestyle intervention program on C-reactive protein: impact of cardiorespiratory fitness in obese adolescents with sleep-related disorders. JOURNAL OF SLEEP RESEARCH. 27

Kidd PS, Alvarez A, Alvarez-Lopez V, Cerdeira-Perez A, Rodriguez-Garrido B, Prieto-Fernandez A, Chalot M.  2021.  Beneficial traits of root endophytes and rhizobacteria associated with plants growing in phytomanaged soils with mixed trace metal-polycyclic aromatic hydrocarbon contamination. CHEMOSPHERE. 277:130272.

De Nonneville A., Jauffret C., Goncalves A., Classe J-M., Cohen M., Reyal F., Mazouni C., Chauvet M-P., Chopin N., Colombo P-E. et al..  2018.  Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast. ANNALS OF ONCOLOGY. 29:62.

De Nonneville A., Jauffret C., Goncalves A., Classe J-M., Cohen M., Reyal F., Mazouni C., Chauvet M-P., Chopin N., Colombo P-E. et al..  2018.  Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast. ANNALS OF ONCOLOGY. 29:62.

de Nonneville A, Goncalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE et al..  2017.  Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. BREAST CANCER RESEARCH AND TREATMENT. 162:307-316.

De Nonneville A., Goncalves A., Boher J-M., Classe J-M., Cohen M., Colombo P-E., Reyal F., Chauvet M-P., Jouve E., Darai E. et al..  2018.  Benefit of adjuvant systemic therapies in HR1 HER2-pT1ab node-negative breast carcinomas. ANNALS OF ONCOLOGY. 29

De Nonneville A., Goncalves A., Boher J-M., Classe J-M., Cohen M., Colombo P-E., Reyal F., Chauvet M-P., Jouve E., Darai E. et al..  2018.  Benefit of adjuvant systemic therapies in HR1 HER2-pT1ab node-negative breast carcinomas. ANNALS OF ONCOLOGY. 29